Logo

VACHU

Voyager Acquisition Corp Unit

VACHU

Voyager Acquisition Corp Unit • NASDAQ
$10.62 ▲ 0.00% (+0.00)
Market Cap $334.99 M
52w High $11.61
52w Low $10.07
Dividend Yield 0%
P/E 0
Volume 51
Outstanding Shares 31.54M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $405.805K ▲ $2.359M ▼ 0% $0.093 ▼ $0 ▲
Q2-2025 $0 $240.935K ▼ $2.492M ▲ 0% $0.099 ▼ $-240.935K ▲
Q1-2025 $0 $265.009K ▲ $2.433M ▼ 0% $0.25 ▼ $-265.009K ▼
Q4-2024 $0 $70.877K ▼ $2.923M ▲ 0% $0.3 ▲ $-70.877K ▲
Q3-2024 $0 $529.234K $1.322M 0% $0.07 $-529.234K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $252.35K ▲ $267.548M ▲ $12.536M ▲ $-12.272M ▼
Q2-2025 $92.494K ▼ $264.824M ▲ $12.171M ▲ $252.653M ▲
Q1-2025 $445.492K ▼ $262.292M ▲ $12.131M ▲ $250.161M ▲
Q4-2024 $668.285K ▼ $259.812M ▲ $12.084M ▲ $247.728M ▲
Q3-2024 $757.895K $256.881M $12.075M $-11.29M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $2.359M ▼ $159.856K ▲ $0 $0 $159.856K ▲ $159.856K ▲
Q2-2025 $2.492M ▲ $-352.998K ▼ $0 $0 $-352.998K ▼ $-352.998K ▼
Q1-2025 $2.433M ▼ $-222.793K ▼ $0 ▲ $0 $-222.793K ▼ $-222.793K ▼
Q4-2024 $2.923M ▲ $-89.609K ▲ $-254.265M $0 ▼ $-89.61K ▼ $-89.609K ▲
Q3-2024 $1.322M $-613.859K $-254.265M $255.612M $732.895K $-613.859K

Five-Year Company Overview

Income Statement

Income Statement VACHU today is essentially a financial shell, not an operating business, so its income statement is very limited. It has no real revenue or operating profit because it is a SPAC whose main purpose is to complete a merger, not to sell products or services. Any reported earnings per share mainly reflect interest on cash held in trust and accounting effects, rather than a recurring, operating profit engine. The real operating income story will only begin once the merger with VERAXA Biotech closes and that business is consolidated.

Balance Sheet

Balance Sheet The balance sheet is small and simple, typical for a recently listed SPAC unit. It is largely backed by cash held for the future merger, with very little or no traditional debt and a thin layer of equity representing the sponsor and public investors. This structure generally means low financial leverage but also no hard assets or diversified operations behind the equity. The balance sheet’s quality and risk profile will change dramatically once VERAXA Biotech’s assets, liabilities, and funding needs are brought in after the transaction.

Cash Flow

Cash Flow Current cash flows are mostly mechanical: funds raised in the IPO are placed in trust, while limited cash is used for SPAC operating costs such as legal, advisory, and listing expenses. There is no underlying business generating recurring operating cash yet. Future cash dynamics will depend on how much money remains in trust after redemptions, any additional financing at merger closing, and then VERAXA’s cash burn as it develops its drug pipeline. Investors should expect negative operating cash flow for some time after the merger, as is typical for early-stage biotech companies.

Competitive Edge

Competitive Edge As a SPAC, VACHU itself has no true competitive position in an operating market; its main differentiator is its management team and its ability to close the planned merger on favorable terms. The future competitive position effectively belongs to VERAXA Biotech, which operates in highly competitive oncology drug development. VERAXA’s edge is expected to come from its proprietary antibody and antibody-drug conjugate platform, its focus on cancer, and a specialized leadership and scientific team. However, the biotech field is crowded and high risk, with many rivals and a long path to proving any lasting competitive advantage.

Innovation and R&D

Innovation and R&D VACHU does not conduct research or develop products; it is a financial vehicle. The innovation story lies entirely with VERAXA Biotech, which is building a pipeline of antibody-based and antibody-drug conjugate therapies for cancer. Its technology platform and focus on next-generation oncology treatments could be a meaningful differentiator if its drug candidates show strong safety and effectiveness in trials. At the same time, this is early-stage, science-driven work, so outcomes are uncertain, timelines are long, and continued funding and partnerships will be crucial.

Summary

VACHU is best understood as a transition vehicle: today it is a blank-check company with minimal operations, simple financials, and capital earmarked for a merger, not a traditional operating firm. The investment and risk profile will pivot once the VERAXA Biotech merger is completed, shifting the focus from cash in trust and SPAC mechanics to drug development progress, clinical trial results, and ongoing funding needs. Strengths include an experienced deal-making team, a planned focus on a high-impact medical area, and a proprietary biotech platform. Key risks include deal execution, potential dilution, the inherently high failure rates in drug development, and heavy dependence on future capital and partnerships to move the oncology pipeline forward.